6
Treatment
Pediatric Patients
High Emetic Risk Antineoplastic Agent
➤ Pediatric patients treated with high-emetic-risk antineoplastic agents
should be offered a three-drug combination
of a 5-HT
3
receptor antagonist, dexamethasone, and aprepitant
(Strong Recommendation; EB-I).
➤ Pediatric patients treated with high-emetic-risk antineoplastic agents
who are unable to receive aprepitant should be offered a two-drug
combination of a 5-HT
3
receptor antagonist and dexamethasone
(Strong Recommendation; EB-I).
➤ Pediatric patients treated with high-emetic-risk antineoplastic agents
who are unable to receive dexamethasone should be offered a two-
drug combination of palonosetron and aprepitant
(Strong Recommendation; EB-I).
Moderate Emetic Risk Antineoplastic Agents
➤ Pediatric patients treated with moderate-emetic-risk antineoplastic
agents should be offered a two-drug combination of a 5-HT
3
receptor
antagonist and dexamethasone (Strong Recommendation; EB-I).
➤ Pediatric patients treated with moderate-emetic-risk antineoplastic
agents who are unable to receive dexamethasone should be offered a
two-drug combination of a 5-HT
3
receptor antagonist and aprepitant
(Weak Recommendation; EB-I).
Low Emetic Risk Antineoplastic Agents
➤ Pediatric patients treated with low-emetic-risk antineoplastic agents
should be offered ondansetron or granisetron
(Strong Recommendation; IC-L).
Minimal Emetic Risk Antineoplastic Agents
➤ Pediatric patients treated with minimal emetic risk antineoplastic
agents should not be offered routine antiemetic prophylaxis (Strong
Recommendation; IC-L).
